Stock GPCR STRUCTURE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Structure Therapeutics Inc.

Equities

GPCR

US86366E1064

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-21 EDT 		5-day change 1st Jan Change
45.57 USD -2.52% Intraday chart for Structure Therapeutics Inc. -5.40% +11.80%
06-07 Structure Therapeutics Closes $547.4 Million Offering MT
06-07 BMO Capital Adjusts Price Target on Structure Therapeutics to $100 From $83, Maintains Outperform Rating MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Structure Therapeutics Closes $547.4 Million Offering
MT
Structure Therapeutics Prices Upsized $476 Million Stock Offering
MT
Structure Therapeutics Plans Offering of American Depositary Shares
MT
Top Midday Gainers
MT
Sector Update: Health Care Stocks Edge Higher Monday Afternoon
MT
Structure Therapeutics Reports Positive Topline Data From Obesity Trial; Shares Jump
MT
Structure Therapeutics' obesity drug meets main goal in mid-stage study
RE
Structure Therapeutics Inc. Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
CI
Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ADRs Edge Higher; Lufax Climbs Almost 46%
DJ
Structure Therapeutics Q4 Loss Widens
MT
Structure Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Structure Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Structure's diabetes pill misses weight-loss expectations in mid-stage trial
RE
Structure Therapeutics Inc. Provides Comprehensive GSBR-1290 Program Update
CI
Structure Therapeutics Q3 Loss Narrows
MT
Structure Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Structure Therapeutics Announces Positive Results From Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
CI
Structure Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GPCR Stock
  4. News Structure Therapeutics Inc.
  5. Highlights